Moreover, using meta-analysis, Song and colleagues concluded that the loss of IFN-γ signalling sensitises tumour cells to immune effector cells in vitro, made tumours more susceptible to the host immune system in vivo, and patient tumours developing mutations in IFN-γ signalling before treatment were more likely to respond to ICBT [55]. Here, IFNG is linked to neoplasm.